Most breast cancers grow slowly enough that a tumor takes two to five years to reach a size you can feel, starting from a single malignant cell. But “breast cancer” is not one disease, and growth rates vary dramatically depending on the molecular subtype, the tumor grade, and your age. Some tumors double in volume every four months; others take nearly a year.
From First Cell to Detectable Lump
A breast cancer cell divides roughly once every one to two months. That sounds slow, but the math is exponential. After 30 doublings, a single cell becomes a billion cells, forming a mass just over one centimeter across (a little more than half an inch, or about a third the size of a golf ball). At a typical division rate, that process takes somewhere between two and five years. This means that by the time you discover a lump during a self-exam, the cancer has been quietly developing for a long time.
Mammography can detect tumors before they’re large enough to feel, which is why screening intervals matter. Cancers that appear between scheduled mammograms, called interval cancers, tend to be faster-growing and more aggressive than those caught during routine screening.
How Subtype Shapes Growth Speed
The single biggest factor in how fast a breast cancer grows is its molecular subtype. Researchers measure growth using “volume doubling time,” the number of days it takes a tumor to double in size. A study using 3D ultrasound found the following averages:
- Luminal A (hormone receptor-positive, low proliferation): about 257 days to double, the slowest of the major subtypes.
- Luminal B (hormone receptor-positive, higher proliferation): about 211 days.
- HER2-positive: about 184 days.
- Triple-negative: about 127 days, roughly twice as fast as luminal A.
The overall median doubling time across all breast cancers in that study was 164 days, just under six months. But the range was enormous, from as fast as 66 days to as slow as 521 days. Two people diagnosed with “breast cancer” can have tumors growing at wildly different speeds.
What Ki-67 Tells You About Proliferation
If you’ve seen a pathology report, you may have noticed a number labeled Ki-67. This is a marker of how many cells in the tumor are actively dividing at the time of biopsy, expressed as a percentage. A Ki-67 of 5% or below signals a slow-growing tumor. A Ki-67 of 30% or higher points to rapid proliferation. The range in between is less clear-cut, which is why doctors sometimes order additional genetic tests for tumors in that gray zone.
Ki-67 is considered the single most powerful individual predictor of growth rate. It’s also one of the key measurements used to distinguish luminal A tumors (typically under 14% to 20%) from the faster-growing luminal B tumors. Among patients with a Ki-67 of 15% or less, five-year survival rates were about 89%, compared with roughly 83% for patients with levels above 45%.
Tumor Grade and What It Means
Tumor grade, assessed under a microscope, is another window into growth speed. The grading system scores three features: how much the cancer cells still resemble normal breast tissue, how varied the cell nuclei look, and how many cells are caught in the act of dividing (the mitotic count). These scores are added together to produce a grade of 1, 2, or 3.
Grade matters for speed. In a large UK screening study, grade 1 tumors had a median doubling time of 317 days (nearly a year), grade 2 tumors doubled in 288 days, and grade 3 tumors doubled in just 195 days. Grade 3 cancers were also more likely to be estrogen receptor-negative, which tracks with the faster doubling times seen in triple-negative disease.
How Long It Takes to Move Between Stages
A study analyzing the natural history of breast cancer using the SEER database estimated progression timelines for untreated tumors. On average, an untreated cancer took about 5.3 years to progress from stage 0 (in situ) to stage I, another 4.6 years from stage I to stage II, about 2.3 years from stage II to stage III, and roughly 1 year from stage III to stage IV. The pattern was similar regardless of estrogen receptor status.
Two things stand out here. First, the earlier stages progress slowly, giving screening a meaningful window to catch disease before it advances. Second, the later stages compress dramatically. The jump from stage III to metastatic disease takes less than a quarter of the time it took for the tumor to move from stage 0 to stage I. Growth accelerates as cancer becomes more advanced, partly because larger, higher-grade tumors have acquired more mutations that fuel faster division.
Inflammatory Breast Cancer: A Different Timeline
Inflammatory breast cancer is a rare but notably aggressive form that doesn’t follow the typical slow-growth pattern. Instead of forming a distinct lump, it causes the breast to become red, swollen, and warm, often resembling an infection. These symptoms can progress in a matter of weeks or months. By definition, the changes have been present for less than six months at diagnosis. Because it mimics other conditions, inflammatory breast cancer is frequently diagnosed late, which contributes to its worse outcomes.
Age, Density, and Hormonal Influences
Younger, premenopausal women tend to develop faster-growing breast cancers. Faster tumor growth was specifically associated with younger age in screening data, and premenopausal women with dense breast tissue were about 70% more likely to be diagnosed at an advanced stage compared to women with less dense breasts. Dense tissue may both mask tumors on imaging and create an environment that supports faster progression.
Postmenopausal women using combination hormone therapy (estrogen plus progestin) for five or more years also showed increased likelihood of being diagnosed at a later stage. The highest risk of advanced disease appeared in women who had both dense breast tissue and active hormonal exposure, whether from premenopausal status or from hormone therapy.
BRCA1 gene mutations add another layer. Tumors arising from BRCA1 mutations tend to have higher mitotic rates and greater lymphatic involvement than cancers that develop without an inherited mutation. These tumors disproportionately fall into the triple-negative category, which partly explains their faster growth.
Why Growth Rate Matters for Screening
Understanding growth speed helps explain why screening recommendations are set the way they are. Cancers detected between mammograms (interval cancers) had a median doubling time of 245 days for the fastest-growing group, compared with 448 days for slower tumors that were technically visible on prior imaging but missed. The gap between these numbers is the practical argument for consistent screening intervals: a tumor growing at triple-negative speed can go from undetectable to clinically significant within a year or two.
For women with dense breast tissue or known risk factors like BRCA mutations, supplemental imaging with breast MRI or ultrasound may catch fast-growing cancers that mammography alone would miss between annual screens.